{"generic":"Cholic Acid","drugs":["Cholbam","Cholic Acid","Orphacol"],"mono":{"0":{"id":"jy7os0","title":"Generic Names","mono":"Cholic Acid"},"1":{"id":"jy7os1","title":"Dosing and Indications","sub":[{"id":"jy7os1b4","title":"Adult Dosing","mono":"<ul><li><b>Bile acid synthesis defect, Due to single enzyme defects:<\/b> 10 to 15 mg\/kg ORALLY once daily or in 2 divided doses with food; discontinue if liver function does not improve within 3 months or if complete biliary obstruction occurs<\/li><li><b>Disorder of peroxisomal function, With liver disease manifestations, steatorrhea, or complications due to decreased absorption of fat soluble vitamins:<\/b> 10 to 15 mg\/kg ORALLY once daily or in 2 divided doses with food; discontinue if liver function does not improve within 3 months or if complete biliary obstruction occurs<\/li><\/ul>"},{"id":"jy7os1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Bile acid synthesis defect, Due to single enzyme defects:<\/b> 3 weeks or older: 10 to 15 mg\/kg ORALLY once daily or in 2 divided doses with food; discontinue if liver function does not improve within 3 months or if complete biliary obstruction occurs<\/li><li><b>Disorder of peroxisomal function, With liver disease manifestations, steatorrhea, or complications due to decreased absorption of fat soluble vitamins:<\/b> 3 weeks or older: 10 to 15 mg\/kg ORALLY once daily or in 2 divided doses with food; discontinue if liver function does not improve within 3 months or if complete biliary obstruction occurs<\/li><\/ul>"},{"id":"jy7os1b6","title":"Dose Adjustments","mono":"<ul><li><b>Persistent, worsening liver function or cholestasis:<\/b> Discontinue use; consider reinitiating at lower dose when liver function returns to baseline.<\/li><li><b>Familial hypertriglyceridemia:<\/b> 11 to 17 mg\/kg orally once daily or in 2 divided doses<\/li><\/ul>"},{"id":"jy7os1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bile acid synthesis defect, Due to single enzyme defects<\/li><li>Disorder of peroxisomal function, With liver disease manifestations, steatorrhea, or complications due to decreased absorption of fat soluble vitamins<\/li><\/ul>"}]},"3":{"id":"jy7os3","title":"Contraindications\/Warnings","sub":[{"id":"jy7os3b9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"jy7os3b10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Newly diagnosed or family history of familial hypertriglyceridemia may cause poor cholic acid absorption; dose adjustment recommended<\/li><li>Hepatic:<\/li><li>-- Exacerbation of liver impairment (eg, elevated bilirubin values, worsening of serum transaminases or cholestasis) has been reported; monitoring recommended and discontinuation may be necessary<\/li><li>-- Concurrent elevations of serum gamma glutamyltransferase (GGT) and ALT may indicate overdose<\/li><li>Concomitant Use:<\/li><li>-- Avoid concomitant cyclosporine use<\/li><\/ul>"},{"id":"jy7os3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"jy7os3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jy7os4","title":"Drug Interactions","sub":{"1":{"id":"jy7os4b14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"},"2":{"id":"jy7os4b15","title":"Moderate","mono":"<ul><li>Aluminum Carbonate, Basic (probable)<\/li><li>Aluminum Hydroxide (probable)<\/li><li>Aluminum Phosphate (probable)<\/li><li>Dihydroxyaluminum Aminoacetate (probable)<\/li><li>Dihydroxyaluminum Sodium Carbonate (probable)<\/li><li>Magaldrate (probable)<\/li><\/ul>"}}},"5":{"id":"jy7os5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Skin lesion (1%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (1%), Diarrhea (2%), Gastro-esophageal reflux disease with esophagitis (1%), Nausea (1%), Polyp of intestine (1%)<\/li><li><b>Hepatic:<\/b>Jaundice (1%)<\/li><li><b>Renal:<\/b>Urinary tract infectious disease (1%)<\/li><li><b>Other:<\/b>Malaise (1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Cholelithiasis<\/li><li><b>Hepatic:<\/b>Abnormal liver function, Exacerbation<\/li><li><b>Neurologic:<\/b>Peripheral nerve disease (1%)<\/li><\/ul>"},"6":{"id":"jy7os6","title":"Drug Name Info","sub":{"0":{"id":"jy7os6b17","title":"US Trade Names","mono":"<ul><li>Orphacol<\/li><li>Cholbam<\/li><\/ul>"},"2":{"id":"jy7os6b19","title":"Class","mono":"Gastrointestinal Agent<br\/>"},"3":{"id":"jy7os6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jy7os6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jy7os7","title":"Mechanism Of Action","mono":"Cholic acid is a bile acid replacement therapy that corrects deficiencies due to defective biosynthesis or intestinal malabsorption. Cholic acid and its conjugates are ligands of a receptor (farnesoid X receptor, or FXR) which regulates enzymes and transporters that are important in bile acid synthesis and in maintaining bile acid homeostasis in the enterohepatic circulation.<br\/>"},"8":{"id":"jy7os8","title":"Pharmacokinetics","sub":{"0":{"id":"jy7os8b23","title":"Absorption","mono":"Bioavailability, Oral: Extensively absorbed <br\/>"},"2":{"id":"jy7os8b25","title":"Metabolism","mono":"Liver: Primary, via conjugation <br\/>"},"3":{"id":"jy7os8b26","title":"Excretion","mono":"<ul><li>Bile: Conjugated cholic acid<\/li><li>Fecal: Unabsorbed cholic acid<\/li><\/ul>"}}},"9":{"id":"jy7os9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>Administer with food.<\/li><li>Do not crush or chew capsules.<\/li><li>For patients unable to swallow the capsule, contents may be added to 1 to 2 tablespoons (15 to 30 mL) of infant formula or breast milk (for young children), or soft food such as mashed potatoes or apple puree (for older children); mix for 30 seconds and administer immediately.<\/li><li>Administer at least 1 hour before or 4 to 6 hours after an aluminum-based antacid or a bile acid binding resin.<\/li><\/ul>"},"10":{"id":"jy7os10","title":"Monitoring","mono":"<ul><li>Reduction or elimination of bile acid metabolites may indicate efficacy<\/li><li>AST, ALT, serum gamma glutamyltransferase, alkaline phosphatase, bilirubin, and INR monthly; for the first 3 months, every 3 months over the next 9 months, every 6 months during the subsequent 3 years, and annually thereafter, with increased monitoring during periods of rapid growth, concomitant disease, and pregnancy<\/li><\/ul>"},"11":{"id":"jy7os11","title":"How Supplied","mono":"<b>Cholbam<\/b><br\/>Oral Capsule: 50 MG, 250 MG<br\/>"},"13":{"id":"jy7os13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to report symptoms of liver impairment or cholestasis.<\/li><li>Side effects may include diarrhea, reflux esophagitis, nausea, abdominal pain, malaise, urinary tract infection, or peripheral neuropathy.<\/li><li>Advise patient to take capsule with food.<\/li><li>Tell caregiver of pediatric patient that capsule contents can be mixed with a liquid or soft food and must be given immediately after mixing.<\/li><li>Direct patient to take drug at least 1 hour before or 4 to 6 hours after a bile acid binding resin or aluminum-based antacid.<\/li><\/ul>"}}}